Non-steroidal anti-inflammatory drugs if combined with anti-histamine and anti-serotonin agents interfere with the bronchial and platelet effects of "platelet-activating factor" (PAF-acether).
暂无分享,去创建一个
[1] B. Vargaftig,et al. Biosynthesis of platelet-activating factor (PAF-ACETHER). II. Involvement of phospholipase A2 in the formation of PAF-ACETHER and lyso-PAF-ACETHER from rabbit platelets. , 1982, Thrombosis research.
[2] B. Vargaftig,et al. Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig. , 1981, European journal of pharmacology.
[3] M. Bristow,et al. Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances. , 1981, Laboratory investigation; a journal of technical methods and pathology.
[4] T. Williams,et al. Control of vascular permeability by polymorphonuclear leukocytes in inflammation , 1981, Nature.
[5] B. Vargaftig,et al. Present concepts on the mechanisms of platelet aggregation. , 1981, Biochemical pharmacology.
[6] B. Vargaftig,et al. Is Phospholipase A2 (PLA2) Involved In PAF-Acether Formation By Platelets , 1981 .
[7] B. Vargaftig,et al. Role of the metabolites of arachidonate in platelet-dependent and independent experimental bronchoconstriction. , 1981, Bulletin europeen de physiopathologie respiratoire.
[8] P. Moore,et al. Human plasma contains prostaglandin 'reciprocal coupling factor'. , 1980, European journal of pharmacology.
[9] B. Vargaftig,et al. Activation of guinea-pig platelets induced by convulxin, a substance extracted from the venom of Crotalus durissus cascavella. , 1980, European journal of pharmacology.
[10] B. Vargaftig,et al. Platelet‐Activating Factor (PAF‐Acether) Secretion from Platelets: Effect of Aggregating Agents , 1980, British journal of haematology.
[11] B. Vargaftig,et al. Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. , 1980, European journal of pharmacology.
[12] B. Vargaftig,et al. L8027 and 1-nonyl-imidazole as non-selective inhibitors of thromboxane synthesis. , 1979, European journal of pharmacology.
[13] D. Hanahan,et al. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). , 1979, The Journal of biological chemistry.
[14] B. Vargaftig,et al. Mechanisms of bronchoconstriction and of thrombocytopenia induced by collagen in the guinea pig. , 1979, European journal of pharmacology.
[15] J. Cazenave,et al. Aggregation of rabbit platelets by platelet-activating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane-active drugs. , 1979, Laboratory investigation; a journal of technical methods and pathology.
[16] B. Vargaftig,et al. The role of platelet-activating factor in platelet aggregation , 1979, Nature.
[17] J. Polonsky,et al. Semi-synthèse et structure proposée du facteur activant les plaquettes (P.A.F.): PAF-acether, un alkyl ether analogue de la lysophosphatidylcholine. , 1979 .
[18] H. Weiss,et al. Secretable storage pools in platelets. , 1979, Annual review of medicine.
[19] B. Vargaftig,et al. ROLE OF PLATELETS IN ASPIRIN‐SENSITIVE BRONCHOCONSTRICTION IN THE GUINEA‐PIG; INTERACTIONS WITH SALICYLIC ACID , 1978, British journal of pharmacology.
[20] J. Cazenave,et al. Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23,187. , 1977, The Journal of laboratory and clinical medicine.
[21] B. Vargaftig. Carrageenan and thrombin trigger prostaglandin synthetase‐independent aggregation of rabbit platelets: inhibition by phospholipase A2 inhibitors * , 1977, The Journal of pharmacy and pharmacology.
[22] B. Vargaftig,et al. Acute hypotension due to carrageenan, arachidonic acid and slow reacting substance C in the rabbit: role of platelets and nature of pharmacological antagonism. , 1977, European journal of pharmacology.
[23] Vargaftig Bb. Involvement of mediators in the interaction of platelets and carrageenan. , 1977 .
[24] Classen Hg,et al. Platelet aggregation induced by anaphylatoxin and its inhibition. , 1975 .
[25] D. Ross,et al. Morphine and Ethanol: Selective Depletion of Regional Brain Calcium , 1974, Science.
[26] B. Vargaftig,et al. Selective inhibition by mepacrine of the release of “rabbit aorta contracting substance” evoked by the administration of bradykinin , 1972, The Journal of pharmacy and pharmacology.
[27] D. Branch,et al. Wavelength Shifts of Intensity Minima in Type I Supernova Spectra , 1971 .
[28] B. Vargaftig,et al. Release of vasoactive substances from guinea-pig lungs by slow-reacting substance c and arachidonic acid. Its blockade by nonsteroid anti-inflammatory agents. , 1971, Pharmacology.
[29] C. Sadavongvivad. Pharmacological significance of biogenic amines in the lungs: 5‐hydroxytryptamine , 1970, British journal of pharmacology.
[30] D. Aviado,et al. Pharmacological significance of biogenic amines in the lungs: histamine , 1970, British journal of pharmacology.
[31] J. Vane,et al. Release of Additional Factors in Anaphylaxis and its Antagonism by Anti-inflammatory Drugs , 1969, Nature.